Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 111

1.

Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6.

Thümmler S, Dor E, David R, Leali G, Battista M, David A, Askenazy F, Verstuyft C.

Front Psychiatry. 2018 Jan 24;9:2. doi: 10.3389/fpsyt.2018.00002. eCollection 2018.

2.

Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063.

Tohyama K, Sudo M, Morohashi A, Kato S, Takahashi J, Tagawa Y.

Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):577-587. doi: 10.1111/bcpt.12964. Epub 2018 Feb 26.

PMID:
29345044
3.

Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.

Shang DW, Wang ZZ, Hu HT, Zhang YF, Ni XJ, Lu HY, Zhang M, Hu JQ, Qiu C, Peng H, Shen LF, Wen YG.

Eur J Clin Pharmacol. 2018 Jan;74(1):61-67. doi: 10.1007/s00228-017-2340-1. Epub 2017 Oct 3.

PMID:
28975417
4.

Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients.

Shi Y, Li M, Song C, Xu Q, Huo R, Shen L, Xing Q, Cui D, Li W, Zhao J, He L, Qin S.

Transl Psychiatry. 2017 Jul 11;7(7):e1170. doi: 10.1038/tp.2017.143.

5.

Risperidone Therapy and CYP2D6 Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2017 Apr 10.

6.

Aripiprazole Therapy and CYP2D6 Genotype.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2016 Sep 22.

7.

Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes.

Dean L.

In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
2016 Jun 8.

8.

Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.

Swathy B, Saradalekshmi KR, Nair IV, Nair C, Banerjee M.

Epigenomics. 2017 Jun;9(6):811-821. doi: 10.2217/epi-2016-0181. Epub 2017 Apr 21.

PMID:
28429622
9.

Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.

Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K.

Int J Neuropsychopharmacol. 2017 Jul 1;20(7):529-537. doi: 10.1093/ijnp/pyx019.

10.

Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors.

Wiciński M, Węclewicz MM, Miętkiewicz M, Malinowski B, Grześk E, Klonowska J.

J Psychiatr Pract. 2017 Mar;23(2):114-120. doi: 10.1097/PRA.0000000000000223. Review.

PMID:
28291036
11.

Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis.

Pei Q, Huang L, Huang J, Gu JK, Kuang Y, Zuo XC, Ding JJ, Tan HY, Guo CX, Liu SK, Yang GP.

Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508. doi: 10.1038/aps.2016.96. Epub 2016 Sep 26.

12.

Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.

Greenberg WM, Citrome L.

Clin Pharmacokinet. 2017 May;56(5):493-503. doi: 10.1007/s40262-016-0465-5. Review.

PMID:
27722855
13.

Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.

Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K.

Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw083. doi: 10.1093/ijnp/pyw083. Print 2016 Dec.

14.

Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis.

Paulzen M, Haen E, Stegmann B, Hiemke C, Gründer G, Lammertz SE, Schoretsanitis G.

Psychoneuroendocrinology. 2016 Nov;73:9-15. doi: 10.1016/j.psyneuen.2016.07.009. Epub 2016 Jul 18.

PMID:
27448523
15.

Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.

Citrome L.

Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109. Review.

PMID:
27440212
16.

Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point.

Andrade C.

J Clin Psychiatry. 2015 Dec;76(12):1633-4. doi: 10.4088/JCP.15f10514.

17.

CYP3A4 activity and haloperidol effects in alcohol addicts.

Zastrozhin MS, Smirnov VV, Sychev DA, Savchenko LM, Bryun EA, Matis OA.

Int J Risk Saf Med. 2015;27 Suppl 1:S23-4. doi: 10.3233/JRS-150676.

PMID:
26639694
18.

Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.

Hwang TJ, Lo WM, Chan HY, Lin CF, Hsieh MH, Liu CC, Liu CM, Hwu HG, Kuo CH, Chen WJ.

J Clin Psychopharmacol. 2015 Dec;35(6):635-44. doi: 10.1097/JCP.0000000000000426.

PMID:
26488675
19.

Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.

Darwish M, Bond M, Yang R, Hellriegel ET, Robertson P.

Clin Drug Investig. 2015 Nov;35(11):725-33. doi: 10.1007/s40261-015-0330-6.

PMID:
26387027
20.

Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine.

Akamine Y, Uehara H, Miura M, Yasui-Furukori N, Uno T.

J Clin Pharm Ther. 2015 Aug;40(4):480-2. doi: 10.1111/jcpt.12286. Epub 2015 May 26.

PMID:
26009790

Supplemental Content

Loading ...
Support Center